Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-4hD29
- Development stage
- Preclinical
- Lead developer
- ULB Center for Diabetes Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-NOTA-4hD29 (also known as [68Ga]Ga-NOTA-4hD29) is a radiolabeled single-domain antibody (nanobody) targeting dipeptidyl peptidase-like protein 6 (DPP6), a cell surface biomarker highly enriched on pancreatic beta cells and to a lesser extent alpha cells. Developed by researchers at the ULB Center for Diabetes Research and Uppsala University, the tracer consists of the camelid-derived anti-DPP6 nanobody 4hD29 conjugated to the bifunctional chelator NOTA and radiolabeled with Gallium-68 (68Ga). It is designed as a non-invasive positron emission tomography (PET) imaging agent to quantify beta cell mass (BCM) in vivo, which can aid in monitoring the progression of type 1 diabetes (T1D) and evaluating the survival of transplanted pancreatic islets or stem cell-derived islets.
- Other names
- 68Ga-labelled anti-DPP6 4hD29 sdAb[68Ga]Ga-NOTA-4hD29[68Ga]NCS-NOTA-4hD29anti-DPP6 4hD29 nanobodyanti-DPP-6 4hD29 nanobodyanti-DPP 6 4hD29 nanobody
02
Targets
DPP6 (Dipeptidyl peptidase 6)DPP6 (Dipeptidyl peptidase-like protein 6)
Beyond the preview
Go deeper on 68Ga-NOTA-4hD29.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-4hD29.